CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Rifampin Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current, To Be Discontinued. First FDA posting: 2021-02-17. Latest FDA row update: 2026-10-05.
FDA lists 4 package records, with companies: Fresenius Kabi USA, LLC, Mylan Institutional LLC, Mylan Institutional, a Viatris Company, Sanofi-Aventis U.S. LLC. Package NDCs: 0068-0597-01, 63323-351-20, 67457-445-60.
FDA shortage reason: Demand increase for the drug; Discontinuation of the manufacture of the drug; Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Fresenius Kabi USA, LLC | 63323-351-20 | Rifampin, Injection, 600 mg (NDC 63323-351-20) | Limited Availability | 2026-09-15 |
| Mylan Institutional, a Viatris Company | 67457-445-60 | Rifampin, Injection, 600 mg (NDC 67457-445-60) | Unavailable | 2026-10-05 |
| Sanofi-Aventis U.S. LLC | 0068-0597-01 | Rifadin, Injection, 600 mg (NDC 0068-0597-01) | Unavailable | 2026-09-18 |
| Sanofi-Aventis U.S. LLC | 0068-0597-01 | Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01) | Not stated | 2026-04-20 |
Source facts
Grouped generic ingredient: Rifampin Injection · 4 package records
Therapeutic categories: Anti-Infective
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.